Compare ITRG & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRG | CSTL |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 640.6M |
| IPO Year | 2017 | 2019 |
| Metric | ITRG | CSTL |
|---|---|---|
| Price | $2.37 | $22.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $5.13 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 3.6M | 324.8K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $67.34 | $2.42 |
| Revenue Next Year | $25.89 | $12.69 |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $1.43 | $14.59 |
| 52 Week High | $4.87 | $44.28 |
| Indicator | ITRG | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 40.54 | 57.70 |
| Support Level | $2.32 | $21.77 |
| Resistance Level | $3.29 | $24.33 |
| Average True Range (ATR) | 0.15 | 0.85 |
| MACD | 0.01 | 0.23 |
| Stochastic Oscillator | 16.30 | 90.40 |
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.